Investors are often known for following stocks that may have gained strong momentum, and those who are looking into such stocks this morning could do well to take a look into Catheter Precision Inc. (NYSE American: VTAK).

The company’s stock gained momentum today after the company showcased its path-breaking 3D mapping system. The company revealed this morning that the product had been showcased at an event. In this context, it could be a good idea to take a closer look at the actual system. It is a non-invasive 3D imaging system that helps physicians identify the origin of arrhythmias.

The product was showcased by the company at the Congresso Nazionale Associazione Italiana di Aritmologia e Cardiostimolazione event that took place in Bologna, Italy, from September 21 to September 23, 2023. The company also revealed that that product would also be showcased at a number of other electrophysiology conferences that would take place soon.

David Jenkins, the interim Chief Executive Officer of Catheter Precision, spoke about the development as well. He noted that the presence of the company at the event in Bologna was a demonstration of its innovative technology.

Additionally, it also led to the strengthening of collaborations with prominent VIVO sites. VIVO is another offering from the company. Those sites included Pisa CNR and Ospedale Della Misericordia Grosseto. In order to further solidify its presence in Italy, Catheter Precision entered into a strategic partnership with Precise Srl.

The company also announced some of the other events where it would showcase VIVO and LockeT, two of its device offerings. The next event would be the Irish Cardiac Society’s 74th Annual Scientific Meeting from October 12 to October 14, followed by the 18th Annual International Symposium on Ventricular Arrythmias from October 13 to October 14. Last but not least would be the 7th Annual Society of Cardiac RN Meeting from October 19 to October 20.